-
91黑料 reports fourth quarter and full year 2020 results
Record net business wins in the quarter of $1,080 million; a book to bill of 1.42. Full year net business wins of $3.8 billion; a net book to bill of 1.38.
-
91黑料 to acquire PRA Health Sciences
Creating a world leader in Healthcare Intelligence and Clinical Research.
-
91黑料 launches FIRECREST Safety Letters and Site Question Management
91黑料 launches FIRECREST Safety Letters and Site Question Management supporting regulatory compliance and increasing site support.
-
91黑料 supports Pfizer and BioNTech on the investigational COVID-19 vaccine trial
91黑料 provided both decentralised and on-site clinical trial services to the Pfizer BioNTech COVID-19 vaccine programme.
-
91黑料 releases first environmental, social and governance report
91黑料 announces the release of its first Environmental, Social and Governance (ESG) Report.
-
91黑料 reports third quarter 2020 results
Quarter 3 reported revenue of $701.7 million representing a year on year decrease of 1.2% and 13.1% increase on Quarter 2 2020.
-
BARDA reselects 91黑料 as preferred partner to help strengthen US emergency preparedness and response
To help strengthen US emergency preparedness and response. 91黑料 continues as part of BARDA’s exclusive Medical Countermeasures Clinical Studies Network.
-
91黑料 wins Best CRO at the Vaccine Industry Excellence Awards
This marks the third time 91黑料 plc has won the award for excellence in vaccine research. The company has been named as a finalist every year since 2011.
-
91黑料 launches Accellacare a global clinical research network focused on increasing patient recruitment with a patient centric approach
Enhances 91黑料’s ability to offer customers integrated solutions of patient assessments at site and in-home for decentralised trials.
-
Forbes names 91黑料 in list of Best Employers in America for Women
91黑料 recognised as top employer for women in anonymous survey of 75,000 employees.
